247 search results for “cancer drug resistance” in the Staff website
-
Bob van de Water
Science
water_b@lacdr.leidenuniv.nl | +31 71 527 6223
-
Peter Bouwman
Science
r.j.p.bouwman@lacdr.leidenuniv.nl | +31 71 527 6105
-
700,000 euros for the fight against aggressive breast cancer
To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…
-
Sebastian Pomplun joins Oncode Institute to accelerate breakthroughs in cancer research
Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…
-
Is a cancer pill a matter of time?
A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.
-
Stiffness and viscosity of cells differ in cancer and other diseases
During illness, the stiffness or viscosity of cells can change. Tom Evers demonstrated this by measuring such properties of human immune cells for the first time. ‘The stiffness of certain cells could be a way to make a diagnosis,’ Evers said. He defended his thesis on March 26th.
-
Antibiotic resistance: an economic problem universities could help to solve
Antibiotic resistance is an economic problem. Pharmaceutical companies cannot earn much from antibiotic research, so they do not invest in it. This makes it important that universities do so, says Ned Buijs.
-
Growth Fund invests many millions in faster and more sustainable (cancer) drug development
On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…
-
Promising new technique to treat cancer receives NWO grant
Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…
-
Developing drugs with artificial intelligence
Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.
-
Hildert Bronkhorst
Science
h.bronkhorst@biology.leidenuniv.nl | +31 71 527 4964
-
Erik Danen
Science
e.danen@lacdr.leidenuniv.nl | +31 71 527 4486
-
New potential drug suppresses chemotherapy induced neuropathic pain
Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.
-
€10.6 million for innovative toolboxes to tackle brain cancer
Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…
-
Researchers tackle antibiotic-resistant bacteria
When a bacterium becomes more resistant to one antibiotic, it sometimes becomes more sensitive to another. To better understand this interaction, researchers from the Leiden Institute of Biology (IBL) and the Leiden Academic Center for Drug Research (LACDR) under supervision of Daniel Rozen and Coen…
-
Combating antibiotic resistance together
Antibiotic resistance is a common problem among patients. The European Project TIPAT trains pharmacologists, microbiologists and immunologists of six universities in interdisciplinary thinking. The ultimate goal is to develop better treatment guidelines to combat resistance. Coen van Hasselt of the…
-
Status update in the evolutionary race between humans and resistant bacteria: two steps forward for us
A patent for what may be a potent, new antibiotic. And: a clear overview of promising approaches to overcome a crucial resistance tactic employed by bacteria. In the span of one week, two researchers from Leiden are receiving their PhDs, each of them on an important step in the battle against bacteria…
-
Alexander Kros
Science
a.kros@chem.leidenuniv.nl | +31 71 527 4234
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
Judith Bovée
Faculteit Geneeskunde
j.v.m.g.bovee@lumc.nl | +31 71 526 9111
-
Hanneke Leegwater
Science
h.leegwater@lacdr.leidenuniv.nl | +31 71 527 6274
-
Ewa Snaar-Jagalska
Science
b.e.snaar-jagalska@biology.leidenuniv.nl | +31 71 527 4980
-
Innovative approach to antibiotic resistance
Resistance to antibiotics is a major problem in health care. Thanks to a grant from the Elise Mathilde Fund and the LUF, pharmacologist dr. Coen van Hasselt can look for new dosing schedules to reduce the development of antibiotic resistance.
-
Helping cancer patients with treatment choices
Researchers at the Leiden Institute of Advanced Computer Science (LIACS) are collaborating on the development of a conversation tool for patients with breast, prostate and skin cancer. The aim is to create a conversation tool that can support cancer patients in their care and help them make decisions.…
-
Giulia Callegaro
Science
g.callegaro@lacdr.leidenuniv.nl | +31 71 527 6105
-
Zware metalen hebben slechte reputatie, maar genezen ook kanker
Veel mensen denken dat zware metalen giftig zijn en mens en natuur altijd schade aanbrengen. Dat beeld moet genuanceerd worden, vindt hoogleraar Sylvestre Bonnet.
-
Sylvestre Bonnet
Science
bonnet@chem.leidenuniv.nl | +31 71 527 4260
-
Special nanoparticles for cancer therapy! Will you help?
Developing a better treatment for patients with head and neck cancer, that is what Binanox, The 2022 iGEM Leiden team, want to achieve. They hope to raise at least 10,000 euros for this cause. Support their crowdfunding campaign today.
-
Artificial intelligence as the co-pilot for drug discovery
There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…
-
Frederic Lens
Science
f.p.lens@biology.leidenuniv.nl | +31 71 527 2727
-
Marcellus Ubbink
Science
m.ubbink@chem.leidenuniv.nl | +31 71 527 4628
-
From discovery to business: 'In the lab, we often don't realise that we are working to help an immense number of patients'
'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…
-
How to develop cancer drugs with less side effects
Lecture, Tuesday Talks: Science Insights
-
goal is to develop antibiotics for tuberculosis with a lower risk of resistance’
Tuberculosis stands as one of the most lethal infectious diseases worldwide. A significant challenge in combatting tuberculosis lies in the emergence of antibiotic resistance triggered by genetic alterations, commonly known as mutations. These mutations can diminish the responsiveness to antibiotics,…
-
Laura Heitman
Science
l.h.heitman@lacdr.leidenuniv.nl | +31 71 527 4558
-
Physics in the picture: cancer cells as an explosion of fireworks
When you think of physics, do you think only of complicated formulas? You’re not the only one. Therefore, every year, the Leiden Insitute of Physics organises the LION Image Award to show another side of physics: beautiful images about intriguing science. The winner of the 2022 photo competition captured…
-
From forming embryo to cancer metastasis: the significance of collective cell movement
Luca Giomi has the first results of his ERC consolidator grant. He discovered that epithelial cells move collectively but in different ways, depending on the scale you look at. It is hexatic at small scales, and becomes nematic at larger scales: it is a multiscale order. This collective movement of…
-
No venom resistance in snake-eating birds: ‘They just don’t need it’
To eat or get eaten. It describes the evolutionary race of snakes versus the mammals and birds that prey on these snakes. Muzaffar Ali Khan devoted his PhD to investigating the molecular mechanisms play of the evolutionary arms race, and has his promotion 16 February. What makes mammals and birds successful…
-
From lab discovery to a new drug: the Venture Challenge makes it possible
A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…
-
Mario van der Stelt
Science
m.van.der.stelt@chem.leidenuniv.nl | +31 71 527 4768
-
Roxanne Kieltyka
Science
r.e.kieltyka@chem.leidenuniv.nl | +31 71 527 4441
-
Gerard van Westen
Science
gerard@lacdr.leidenuniv.nl | +31 71 527 3511
-
Eline Dekeyster
Faculteit der Sociale Wetenschappen
e.a.g.dekeyster@fsw.leidenuniv.nl | +31 71 527 2727
-
Madeline Kavanagh
Science
m.e.kavanagh@lic.leidenuniv.nl | +31 71 527 3527
-
Dutch Cancer Society allocates funds to a mathematician: for treating Ewing sarcoma with the help of an app
If doctors could better estimate a patient's chances of survival, this would help in choosing a specific treatment. It would be particularly beneficial for the rare and malignant Ewing sarcoma, which mainly affects children and adolescents. Mathematics professor Marta Fiocco has been awarded a substantial…
-
Lioe-Fee de Geus-Oei
Faculteit Geneeskunde
l.f.de_geus-oei@lumc.nl | +31 71 526 9111
-
Seeking new concepts to treat diseases
Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’
-
Improving nature’s antibiotic
'What nature made isn’t necessarily an optimized medicine to use in the human body,’ says Professor of Biological Chemistry Nathaniel Martin. That’s why a group of Leiden researchers is making a chemistry-based improved version of the frequently used antibiotic vancomycin. They received an NWO NACTAR…
-
Remarkable PhD research: diagnosing sepsis in premature babies
How can we diagnose the life-threatening condition sepsis in premature babies as quickly and accurately as possible? That is what PhD student Manchu Thangavelu from the Leiden Academic Centre for Drug Research (LACDR) wants to figure out.
-
Skin researcher calls for multidisciplinary collaboration: ‘I want to pool expertise’
In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…